Human lung immunity against Mycobacterium tuberculosis: insights into pathogenesis and protection.
about
A nonhuman primate toxicology and immunogenicity study evaluating aerosol delivery of AERAS-402/Ad35 vaccine: Evidence for transient t cell responses in peripheral blood and robust sustained responses in the lungsCorrelation of mycobacterium tuberculosis specific and non-specific quantitative Th1 T-cell responses with bacillary load in a high burden settingPermutations of time and place in tuberculosisExpansion of CD25-Negative Forkhead Box P3-Positive T Cells during HIV and Mycobacterium tuberculosis InfectionDoxycycline and HIV infection suppress tuberculosis-induced matrix metalloproteinases.Adherent human alveolar macrophages exhibit a transient pro-inflammatory profile that confounds responses to innate immune stimulationDetection of IS6110 and HupB gene sequences of Mycobacterium tuberculosis and bovis in the aortic tissue of patients with Takayasu's arteritis.Asymptomatic HIV-infected individuals on antiretroviral therapy exhibit impaired lung CD4(+) T-cell responses to mycobacteria.miR-582-5p is upregulated in patients with active tuberculosis and inhibits apoptosis of monocytes by targeting FOXO1.Immunodiagnosis of tuberculosis: a dynamic view of biomarker discoveryModulation of Human Macrophage Responses to Mycobacterium tuberculosis by Silver Nanoparticles of Different Size and Surface Modification.Modeling In Vivo Interactions of Engineered Nanoparticles in the Pulmonary Alveolar Lining Fluid.IL-17RA in Non-Hematopoietic Cells Controls CXCL-1 and 5 Critical to Recruit Neutrophils to the Lung of Mycobacteria-Infected Mice during the Adaptive Immune ResponseB cells and antibodies in the defense against Mycobacterium tuberculosis infectionDecreased IL-17 during treatment of sputum smear-positive pulmonary tuberculosis due to increased regulatory T cells and IL-10Redefining latent tuberculosis.An update on vaccines for tuberculosis - there is more to it than just waning of BCG efficacy with time.Harnessing local and systemic immunity for vaccines against tuberculosis.Early clearance of Mycobacterium tuberculosis: a new frontier in prevention.How do we manage and treat a patient with multiple sclerosis at risk of tuberculosis?Type I, II, and III Interferons: Regulating Immunity to Mycobacterium tuberculosis Infection.Sputum is a surrogate for bronchoalveolar lavage for monitoring Mycobacterium tuberculosis transcriptional profiles in TB patientsPlasma contributes to the antimicrobial activity of whole blood against Mycobacterium tuberculosis.Cigarette smoke impairs cytokine responses and BCG containment in alveolar macrophages.Interferon lambda-2 levels in sputum of patients with pulmonary Mycobacterium tuberculosis infection.Lack of Mycobacterium tuberculosis-specific interleukin-17A-producing CD4+ T cells in active disease.Pulmonary immune responses to Mycobacterium tuberculosis in exposed individuals.Differential Immune Responses and Protective Effects in Avirulent Mycobacterial Strains Vaccinated BALB/c Mice.Mycobacterium tuberculosis Invasion of the Human Lung: First Contact.Sera from patients with active pulmonary tuberculosis and their household contacts induce nuclear changes in neutrophils
P2860
Q28396228-3C5EB293-4970-4294-AFE0-A6384803FA45Q28729742-7CD9C0AB-8095-42FA-9564-A07EADE2FF1AQ30378562-BE2BD843-ECA4-423F-86A8-9E25CD90182EQ33650173-12C2CC6C-ACB8-49C3-B946-61597C799C68Q34255402-47322415-7E90-4809-B5DF-610C89041145Q34328868-9C833739-3300-41AB-BB31-7DF663CF5AB3Q34385450-91C40DED-C0BB-4850-B144-E078115EE2D3Q34986921-DD241079-288A-43B3-994B-0786D85061AAQ35036391-9553647A-609A-40E9-A5C5-07D3141EF8F1Q35361654-54BB2DF1-BCAB-4194-A1EB-78EA81240973Q35844923-0D06A43D-F71A-404A-AE11-D667239F638EQ35906427-251124A5-CF22-43B8-980D-2BB6EED7EFACQ35922094-2778DC77-6321-4F8F-A57A-1AD1511E7C55Q36238031-521B4627-7311-4DBE-8A2D-1EE1C079CF05Q37015140-0F0F0A06-C8E5-423C-AEF2-DC0532D8D26EQ37940571-716F1873-D88C-46FA-90E2-6F89BDA99E56Q38041566-4DF37584-F5D6-4D5C-82D3-3BA85EC959E2Q38164196-C2459A19-C2CD-413D-BDB6-C4A6FD3ABE33Q38206209-B9A8BF12-A9AA-428B-88F8-63FC0DF98E45Q38252979-B0EA55B6-2EA5-408B-AEC1-E367F504111BQ38585398-413C664E-31AF-4DE1-A345-618099FECDB5Q39017100-DE60A3A5-3CB5-466D-88A7-F24C0E8E3C7EQ40565501-3ED9FC9E-E6F1-48C9-AB0B-B9661D501F4BQ41103427-D7F99572-1CEC-44EA-A89D-7BC643708C42Q43956133-4D0E8C59-CA7A-4C0B-A203-884881087532Q44318621-F4F7C83C-70E6-4399-A47B-A3E15A7EB1A9Q45544527-0C169567-A2E6-48BA-B1A3-E85C2D1E7CF5Q46726086-983CF9DC-0420-4D3C-A95E-2C31DFAD88DDQ55437997-FC52A1DC-5E9F-4654-9B21-B8C1EE9A535DQ57816204-6A13D7F8-0EA8-4C80-9A68-3CC85BB4FC6F
P2860
Human lung immunity against Mycobacterium tuberculosis: insights into pathogenesis and protection.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Human lung immunity against My ...... o pathogenesis and protection.
@ast
Human lung immunity against My ...... o pathogenesis and protection.
@en
Human lung immunity against My ...... o pathogenesis and protection.
@nl
type
label
Human lung immunity against My ...... o pathogenesis and protection.
@ast
Human lung immunity against My ...... o pathogenesis and protection.
@en
Human lung immunity against My ...... o pathogenesis and protection.
@nl
prefLabel
Human lung immunity against My ...... o pathogenesis and protection.
@ast
Human lung immunity against My ...... o pathogenesis and protection.
@en
Human lung immunity against My ...... o pathogenesis and protection.
@nl
P2860
P1476
Human lung immunity against My ...... o pathogenesis and protection.
@en
P2093
Stephan Schwander
P2860
P304
P356
10.1164/RCCM.201006-0963PP
P407
P577
2010-11-12T00:00:00Z